Generic placeholder image

Inflammation & Allergy - Drug Targets (Discontinued)


ISSN (Print): 1871-5281
ISSN (Online): 2212-4055

Nitric Oxide and Inflammation

Author(s): Giuseppe Cirino, Eleonora Distrutti and John L. Wallace

Volume 5, Issue 2, 2006

Page: [115 - 119] Pages: 5

DOI: 10.2174/187152806776383143

Price: $65


There are several pre-clinical studies on the involvement of NO in inflammation. From this large amount of information it is clear that virtually every cell and many immunological parameters are modulated by NO. Thus, the final outcome is that NO cannot be rigidly classified as an anti-inflammatory or pro-inflammatory molecule. This peculiar aspect of the pathophysiology of NO has hampered the development of new drugs based on the concepts developed. Recent therapeutic approach are targeted to increase endogenous NO by activating the gene and some promising early data are available. At the present stage one of the most promising approach in the inflammation field is represented by a new class of NO-releasing compounds namely NO-NSAIDs that have recently enrolled in phase 2 clinical studies.

Keywords: NO, inflammation, NO-NSAIDs, pre-clinical data, clinical data

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy